Skip to main content

TableĀ 4 Mean base case results

From: Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Country Results LYs QALYs Costs (USD) ICER ($/QALY) ICER ($/LY)
Congo No Tzb arm 8.88 7.72 2588 20,520 19,701
Tzb arm 9.89 8.69 22,585
Diffrence 1.01 0.97 19,997
Ethiopia No Tzb arm 8.87 7.71 3541 19,990 19,384
Tzb arm 9.90 8.70 23,457
Diffrence 1.03 1.00 19,916
Guinea No Tzb arm 8.65 7.52 2955 20,692 20,025
Tzb arm 9.65 8.48 22,898
Diffrence 1.00 0.96 19,943
Kenya No Tzb arm 8.96 7.79 7467 19,601 18,709
Tzb arm 10.03 8.80 27,448
Diffrence 1.07 1.02 19,982
Namibia No Tzb arm 8.69 7.54 25,549 19,818 19,125
Tzb arm 9.72 8.53 45,173
Diffrence 1.03 0.99 19,624
Nigeria No Tzb arm 8.51 7.39 14,066 21,697 21,321
Tzb arm 9.43 8.29 33,628
Diffrence 0.92 0.90 19,561
Rwanda No Tzb arm 8.98 7.80 3919 19,751 19,004
Tzb arm 10.03 8.81 23,894
Diffrence 1.05 1.01 19,975
Uganda No Tzb arm 8.79 7.63 3793 20,477 19,806
Tzb arm 9.80 8.61 23,738
Diffrence 1.01 0.97 19,945
Zambia No Tzb arm 8.75 7.60 7116 20,330 19,473
Tzb arm 9.77 8.58 27,074
Diffrence 1.02 0.98 19,958
Zimbabwe No Tzb arm 8.57 7.44 5458 20,537 20,086
Tzb arm 9.56 8.41 25,303
Diffrence 0.99 0.97 19,845
South Africa No Tzb arm 8.76 7.61 31,160 19,534 18,719
Tzb arm 9.83 8.63 51,119
Diffrence 1.07 1.02 19,960
  1. The standard error for LYs, QALYs, trastuzumab cost and no trastuzumab cost ranged from 0.052 LYs to 0.056 LYs, 0.049 QALYs to 0.053 QALYs, 27 USD to 328 USD, and 27 USD to 324 USD respectively